Cell News and Research

RSS

Researchers discover reason why breast cancer cells become drug resistant

Breast cancer treatments such as Herceptin that target a marker called HER2 have dramatically improved outcomes for women with this type of cancer. But nearly half of these cancers are resistant to Herceptin from the start and almost all of them will eventually become resistant.

21 Jul 2012

Pfizer receives positive opinion from EMA CHMP for crizotinib to treat ALK-positive NSCLC

Pfizer announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that crizotinib be granted conditional marketing authorization in the European Union (EU), for the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).

21 Jul 2012

Experts examine host recognition of Staphylococcus and E.coli bacteria

We are surrounded by bacteria, viruses, fungi and parasites. The fact that we nevertheless do not fall prey to infections is thanks to certain cellular sensor molecules such as toll-like receptors (TLR), which recognize the molecular structure of pathogens and intercede by ensuring an often completely unnoticeable elimination of the invaders. Their immune-activating abilities were only detected in 1998, a discovery which was awarded with the Nobel Prize

21 Jul 2012

Marshall University faculty member receives $426,000 NIH grant for lung cancer study

A Marshall University faculty member has been awarded a three-year, $426,000 grant by the National Institutes of Health (NIH) to further her lung cancer research.

21 Jul 2012

Study explores role of L. reuteri against foodborne infection

While many bacteria exist as aggressive pathogens, causing diseases ranging from tuberculosis and cholera, to plague, diphtheria and toxic shock syndrome, others play a less malevolent role and some are critical for human health.

21 Jul 2012

RPB awards $110,000 grant to Mass. Eye and Ear and HMS for research into blinding diseases

Research to Prevent Blindness (RPB) has awarded a grant of $110,000 to the Massachusetts Eye and Ear Infirmary to support research into the causes, treatment and prevention of blinding diseases. The research will be directed by Joan W. Miller, M.D., Chief of the Mass. Eye and Ear and Mass. General Hospital's Departments of Ophthalmology and Chair of the Department of Ophthalmology at Harvard Medical School.

21 Jul 2012

Scientists uncover how internal mechanisms in nerve cells wire the brain

Scientists at the University of Manchester have uncovered how the internal mechanisms in nerve cells wire the brain. The findings open up new avenues in the investigation of neurodegenerative diseases by analysing the cellular processes underlying these conditions.

21 Jul 2012

Novartis receives FDA approval for Afinitor to treat HER2-negative breast cancer

The U.S. Food and Drug Administration today approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced hormone-receptor positive, HER2-negative breast cancer.

21 Jul 2012

Placenta-derived endothelial colony-forming cells are more vasculogenic: Study

A study comparing whether endothelial colony-forming cells (ECFCs) derived from human placenta or those derived from human umbilical cord blood are more proliferative and better for forming new blood vessels has found that ECFCs derived from human placenta are more vasculogenic.

20 Jul 2012

New class of chemically produced antimicrobial agents could become future infection treatment alternative

The World Health Organization (WHO) has named antimicrobial resistance one of the most important threats to human health. We therefore need to find new compounds that can be used as future alternatives to conventional antibiotics.

20 Jul 2012

Natural compound can virtually eradicate HIV in infected culture cells

A new study by scientists on the Florida campus of The Scripps Research Institute shows, in cell culture, a natural compound can virtually eliminate human immunodeficiency virus (HIV) in infected cells. The compound defines a novel class of HIV anti-viral drugs endowed with the capacity to repress viral replication in acutely and chronically infected cells.

20 Jul 2012

Moderate alcohol consumption may reduce risk of kidney cancer

A majority of previous epidemiologic studies have shown that moderate drinking is associated with a lower risk of kidney cancer, which may affect about 1% of the general population. In published prospective cohort studies, the risk for such cancer among moderate drinkers is usually about 25% less than the risk seen among non-drinkers.

20 Jul 2012

SGC, Life Technologies to generate first-ever master set of epigenetic recombinant antibodies

Life Technologies Corporation today announced it has signed a collaborative partnership with the Structural Genomics Consortium (SGC), and several groups of leading expert scientists in antibody technology at the Universities of Chicago and Toronto, to generate a first-ever master set of quality epigenetic recombinant antibodies for use in disease-related research.

20 Jul 2012

Studies report on therapeutic efficacy of stem cell transplantation in animal models of ALS, SCI

Two studies published in a recent issue of Cell Medicine report on the therapeutic efficacy of stem cell transplantation in animal models of amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI).

20 Jul 2012

New blood sugar monitor: An interview with Sherita Hill Golden

Type 1 diabetes is a disorder in which the body makes proteins (antibodies) against the cells in the pancreas that produce insulin, destroying those cells. As a result, individuals are unable to secrete insulin to normalize blood sugar and hyperglycemia results.

20 Jul 2012

Researchers identify six genes with driving mutations in melanoma

It's been a burning question in melanoma research: Tumor cells are full of ultraviolet (UV)-induced genetic damage caused by sunlight exposure, but which mutations drive this cancer? None have been conclusively tied to melanoma. The sheer abundance of these passenger mutations has obscured the search for genetic driver mutations that actually matter in melanoma development and progression.

20 Jul 2012

Internal clock of human skin responsible for time-based steering of repair and regeneration

A research team at Charité - Universitätsmedizin Berlin together with scientists at a company in Hamburg has now discovered that human skin has an internal clock responsible for the time-based steering of its repair and regeneration, among other things. The team published its first results from their basic research in the current issue of Proceedings of the Academy of Science (PNAS).

20 Jul 2012

Study helps explain why leukemia occurs more frequently as people age

Hundreds of mutations exist in leukemia cells at the time of diagnosis, but nearly all occur randomly as a part of normal aging and are not related to cancer, new research shows.

20 Jul 2012

Conatus, University of Alberta initiate islet cell transplant Phase I/II trial of emricasan for diabetes

Conatus Pharmaceuticals Inc. and the University of Alberta announced today the treatment of the first patient in an investigator-initiated islet cell transplant Phase I/II trial of emricasan (IDN-6556), a pan-caspase inhibitor.

20 Jul 2012

Actinium completes Actimab-A Phase I/II study on Acute Myeloid Leukemia

Actinium Pharmaceuticals, Inc. a biotechnology company focused on developing innovative, alpha particle radiotherapy targeted cancer treatments addressing major unmet medical needs, today announced that it has successfully treated the first cohort of patients in a Phase I/II study of Actimab-A in Acute Myeloid Leukemia (AML) clinical trial. Patients were treated at Memorial Sloan Kettering Cancer Center in New York City.

20 Jul 2012

Cell News and Research

Researchers discover reason why breast cancer cells become drug resistant

Pfizer receives positive opinion from EMA CHMP for crizotinib to treat ALK-positive NSCLC

Experts examine host recognition of Staphylococcus and E.coli bacteria

Marshall University faculty member receives $426,000 NIH grant for lung cancer study

Study explores role of L. reuteri against foodborne infection

RPB awards $110,000 grant to Mass. Eye and Ear and HMS for research into blinding diseases

Scientists uncover how internal mechanisms in nerve cells wire the brain

Novartis receives FDA approval for Afinitor to treat HER2-negative breast cancer

Placenta-derived endothelial colony-forming cells are more vasculogenic: Study

New class of chemically produced antimicrobial agents could become future infection treatment alternative

Natural compound can virtually eradicate HIV in infected culture cells

Moderate alcohol consumption may reduce risk of kidney cancer

SGC, Life Technologies to generate first-ever master set of epigenetic recombinant antibodies

Studies report on therapeutic efficacy of stem cell transplantation in animal models of ALS, SCI

New blood sugar monitor: An interview with Sherita Hill Golden

Researchers identify six genes with driving mutations in melanoma

Internal clock of human skin responsible for time-based steering of repair and regeneration

Study helps explain why leukemia occurs more frequently as people age

Conatus, University of Alberta initiate islet cell transplant Phase I/II trial of emricasan for diabetes

Actinium completes Actimab-A Phase I/II study on Acute Myeloid Leukemia

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News